Liver Cancer HepaSphere Combined With Cryosurgery
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA）combined with cryosurgery for liver cancer.
Liver Cancer
PROCEDURE: HepaSphere combined with cryosurgery
Number of participants with Adverse events, 1 year
Percentage of lesions interventional therapy that show no sign of recurrence 12 months after, 1 year|Progress free disease (PFS), 1 year|Overall survival (OS), 3 year
By enrolling patients with liver cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） combined with cryosurgery for liver cancer.